Emory University, Department of Health Policy and Management, 1518 Clifton, Room 608, Atlanta, GA 30322, USA.
Expert Rev Pharmacoecon Outcomes Res. 2004 Aug;4(4):421-8. doi: 10.1586/14737167.4.4.421.
The objective of this review is to investigate the impact of asthma on Part A and B expenditures for enrollees in the Medicare program, and the effect of voluntary outpatient prescription drug coverage on Medicare-covered asthma expenditures. Data were drawn from the 2001 Medicare Current Beneficiary Survey Access to Care file, a nationally representative sample of the Medicare population, and includes data on individual healthcare expenditures and characteristics, such as health status. Using regression analysis, it was found that self-reported asthma increased the probability of Part A (hospital) expenditures and the level of Part B (outpatient) expenditures. Voluntary prescription drug coverage decreased Part B spending on people with self-reported asthma by 7% but increased Part B spending by 23% for those without asthma. Prescription drug coverage had no effect on the level of Part A expenditures in either those with or without self-reported asthma. The author's study suggests that increases in spending associated with the new Medicare prescription drug benefit may be mitigated by reductions in spending on chronic illnesses such as asthma. As the drug benefit is designed over the next 2 years, attention may need to be focused on the identification of medications that reduce overall Medicare spending to ensure that they are covered by the drug plans.
本研究旨在调查哮喘对 Medicare 项目参保者 A 部分和 B 部分支出的影响,以及非强制性门诊处方药覆盖对 Medicare 覆盖的哮喘支出的影响。数据来自于 2001 年 Medicare 现收现付受益人调查获取的医疗服务文件,这是 Medicare 人群的全国代表性样本,包括个人医疗支出和健康状况等特征的数据。回归分析发现,自我报告的哮喘增加了 A 部分(医院)支出和 B 部分(门诊)支出的概率。自愿处方药物覆盖降低了自我报告有哮喘者的 B 部分支出 7%,但增加了无哮喘者的 B 部分支出 23%。处方药物覆盖对有或无自我报告哮喘者的 A 部分支出水平均无影响。作者的研究表明,与新的 Medicare 处方药福利相关的支出增加可能会因慢性病(如哮喘)支出的减少而得到缓解。随着药物福利在未来 2 年内的制定,可能需要关注减少总体 Medicare 支出的药物,以确保这些药物纳入药物计划。